Gene activation regresses atherosclerosis, promotes health, and enhances longevity

Lipids in Health and Disease

Volumn 9, Issue , 2010, Pages

  Luoma, Pauli V ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; APOLIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE ALPHA; TRANSFERASE; UNCLASSIFIED DRUG; XENOBIOTIC AGENT;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; COGNITION; DIET; DRUG MECHANISM; GENE ACTIVATION; HUMAN; INFLAMMATION; LIFE EXPECTANCY; METABOLIC DISORDER; OXIDATION; PHYSICAL ACTIVITY; PREVALENCE; REVIEW; THROMBOSIS; GENETICS; HEALTH; LONGEVITY; TRANSCRIPTION INITIATION;

ATHEROSCLEROSIS; HEALTH; HUMANS; LONGEVITY; TRANSCRIPTIONAL ACTIVATION;

EID: 77955036273     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-9-67     Document Type: Review

References (115)

1. Glucocorticoid signaling in the cell: expanding clinical implications to complex human behavioral and somatic disorders. GP Chrousos T Kino, Ann NY Acad Sci 2009 1179 153 166 10.1111/j.1749-6632.2009.04988.x 19906238
2. The international burden of cardiovascular disease: responding to the emerging global epidemic. RO Bonow LA Smaha SC Smith Jr GA Mensah C Lenfant, Circulation 2002 106 1602 1605 10.1161/01.CIR.0000035036.22612.2B 12270848
3. High-density lipoprotein as a protective factor against coronary heart disease. T Gordon WP Castelli MC Hjortland WB Kannel TR Dawber, Am J Med 1977 62 707 714 10.1016/0002-9343(77)90874-9 193398
4. Clinical and Metabolic Aspects of High-density Lipopropteins. NE Miller GJ Miller, Amsterdam: Elsevier 1984
5. Plasma high density lipoprotein and liver microsomal enzyme activity in man. PV Luoma EA Sotaniemi RO Pelkonen C Ehnholm, The Medical Research Council 1977-1979 Helsinki: The Academy of Finland, Edited by: Pilli-Sihvola AS, Laaksovirta T, 1980 71
6. Gene activation, apolipoprotein A-I/high density lipoprotein, atherosclerosis prevention and longevity. PV Luoma, Pharmacol Toxicol 1997 81 57 6 10.1111/j.1600-0773.1997.tb00032.x 9298501
7. The LDL receptor. JL Goldstein MS Brown, Arterioscler Thromb Vasc Biol 2009 29 431 438 10.1161/ATVBAHA.108.179564 19299327
8. Increased production of apolipoprotein A-I associated with elevated plasma levels of high-density lipoproteins, apolipoprotein A-I, and lipoprotein A-I in a patient with familial hyperalphalipoproteinemia. DJ Rader JR Schaefer P Lohse K Ikewaki F Thomas WA Harris LA Zech CA Dujovne HB Brewer Jr, Metabolism 1993 42 1429 1434 10.1016/0026-0495(93)90194-S 8231838
9. Heterogeneity of apolipoprotein AI in turnover in subjects with reduced concentrations of plasma high density lipoprotein cholesterol. NA Le HN Ginsberg, Metabolism 1988 37 614 617 10.1016/0026-0495(88)90077-7 3133537
10. Induction and lipoproteins. PV Luoma EA Sotaniemi RO Pelkonen MJ Savolainen C Ehnholm, Lancet 1982 1 625 10.1016/S0140-6736(82)91782-2 6121210
11. Plasma high density lipoprotein and liver lipids and proteins in man. Relation to hepatic histology and microsomal enzyme induction. PV Luoma MJ Savolainen EA Sotaniemi RO Pelkonen AJ Arranto C Ehnholm, Acta Med Scand 1983 214 103 109 6624542
12. Inhibition of early atherogenesis in transgenic mice by human apoprotein A-I. EM Rubin MR Krauss EA Spangler JG Verstuyft MS Clift, Nature 1991 353 265 267 10.1038/353265a0 1910153
13. Effect of recombinant Apo AI Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. SE Nissen T Tsunoda EM Tucsu P Schoenhagen CJ Cooper M Yasin GM Eaton MA Lauer WS Sheldon S Halpern T Crowe JC Blankenship R Kerensky, JAMA 2003 290 2292 2300 10.1001/jama.290.17.2292 14600188
14. Hepatic CTP: phosphocholine cytidylyltransferase- is a critical predictor of plasma high density lipoprotein and very low density lipoprotein. RL Jacobs S Lingrell Y Zhao GA Francis DE Vance, J Biol Chem 2008 283 2143 2155
15. Oxysterols.Friends, foes, or just fellow passengers. I Björkhem U Diczfalusy, Arterioscler Thromb Vasc Biol 2002 22 734 742 10.1161/01.ATV. 0000013312.32196.49 12006384
16. Clinical importance of the cytochromes P450. DW Nebert DW Russell, Lancet 2002 360 1155 1162 10.1016/S0140-6736(02)11203-7 12387968
17. Human cholesterol 7- hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype. CR Pullinger C Eng G Salen S Shefer AK Barra SK Erickson A Verhagen CR Rivera SJ Mulvihill MJ Malloy JP Kan, J Clin Invest 2002 110 109 117 12093894
18. Mortality and cholesterol metabolism in familial hypercholesterolemia. Long-term follow-up of 96 patients. TA Miettinen H Gylling, Arteriosclerosis 1988 8 163 167 3348758
19. Effect of different antilipidemic agents and diets on mortality. M Studer M Briel B Leimenstoll TR Glass HC Bucher, Arch Int Med 2005 165 725 730 10.1001/archinte.165.7.725 (Pubitemid 40569423)
20. Enzymatic reduction of oxysterols impairs LXR signaling in cultured cells and the livers of mice. W Chen G Chen DL Head DJ Mangelsdorf DW Russell, Cell Metab 2007 5 73 79 10.1016/j.cmet.2006.11.012 17189208
21. Liver X receptor in cholesterol metabolism. C Zhao K Dahlman-Wright, J Endocrinol 2010 204 233 240 10.1677/JOE-09-0271 19837721
22. Are side-chain oxidized oxysterols regulators also in vivo? I Björkhem, J Lipid Res 2009 50 213 218 10.1194/jlr.R800025-JLR200 18952574
23. Side chain oxysterol regulates cellular cholesterol homeostasis through direct sterol-membrane interactions. SE Gale EM Westover N Dudley K Krishnan S Merlin DE Scherrer X Han X Zhai HL Brockman RE Brown DF Covey JE Schafffer P Schlesinger DS Ory, J Biol Chem 2009 284 1755 1764 10.1074/jbc.M807210200 18996837
24. SREBP-2 positively regulates transcription of the cholesterol efflux gene, ABCA1, by generating oxysterol ligands for LXR. J Wong C Quinn AJ Brown, Biochem J 2007 400 485 489
25. Vascular cytochrome P450 enzymes: Physiology and pathophysiology. I Fleming, TCM 2008 18 20 24 18206805
26. Action of epoxyeicosatrienoic acids on cellular function. AA Spector AW Norris, Am J Physiol Cell Physiol 2007 292 996 C1012 10.1152/ajpcell.00402.2006 16987999
27. Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2. M Spiecker H Darius T Hankeln S Muhidien AM Sattler JR Schaefer K Node J Börgel A Mgge K Lindpainter A Huesing B Maisch DC Zeldin JK Liao, Circulation 2004 110 2132 2136 10.1161/01.CIR.0000143832. 91812.60 15466638
28. Cytochrome 450 eicosanoids are activators of peroxisome proliferator-activated receptor V Ng Y Huang LM Reddy JR Falck ET Lin DL Kroetz, Drug Metab Dispos 2007 35 1126 1134 10.1124/dmd.106.013839 17431031
29. Oxysterol activation of phosphatidylcholine synthesis involves CTP:phosphocholine cytidylyltransferase translocation to the nucleus. K Gehrig TA Lagace ND Ridgway, Biochem J 2009 418 209 217 10.1042/BJ20081923 18980580
30. Fasting-dependent glucose and lipid metabolic response through hepatic sirtuin 1. JT Rodgers P Puigserver, PNAS 2007 104 12861 12866 10.1073/pnas.0702509104 17646659
31. SIRT1 deacetylates and positively regulates the nuclear receptor LXR. X Li S Zhang G Blander JG Tse M Krieger L Guarente, Mol Cell 2007 28 91 106 10.1016/j.molcel.2007.07.032 17936707
32. SIRT1: roles in aging and cancer. EJ Kim SJ Um, BMB Reports 2008 41 751 756 19017485
33. DisSirting on LXR and cholesterol metabolism. JM Feige J Auwerx, Cell Metab 2007 6 343 345 10.1016/j.cmet.2007.10.003 17983578
34. Variation in paraoxonase-1 activity and atherosclerosis. H Soran NN Younis V Charlton-Menys P Durrington, Curr Opin Lipidol 2009 20 265 274 10.1097/MOL.0b013e32832ec141 19550323
35. Paraoxonase gene polymorphisms are associated with carotid arterial thickness in subjects with familial hypercholesterolemia. FR Leus ME Wittekoek J Prins JJP Kastelein HAM Voorbij, Atherosclerosis 2000 149 371 377 10.1016/S0021-9150(99)00324-X 10729387
36. Nuclear receptors: Decoding metabolic disease. J Sonoda L Pei RM Evans, FEBS Letters 2008 582 2 9 10.1016/j.febslet.2007.11.016 18023286
37. Liver X receptors signalling pathways in cardiovascular disease. P Tontonoz DJ Mangelsdorf, Mol Endocrinol 2003 17 985 993 10.1210/me.2003-0061 12690094
38. Niemann-Pick C1like gene expression is downregulated by LXR activators in the intestine. C Duval V Touche A Tailleux JC Fruchart C Fievet V Clavey B Staels S Lestavel, Biochem Biophys Res Commun 2006 340 1259 1263 10.1016/j.bbrc.2005.12.137 16414355
39. Regulation of cholesterologenesis by the oxysterol receptor LXR Y Wang PM Rogers C Su G Varga KR Stayrook TP Burris, J Biol Chem 2008 283 26332 2639 10.1074/jbc.M804808200 18676367
40. Regulation of macrophage functions by PPAR, PPAR, and LXRs in mice and men. Rigamonti G Chinetti-Ghaguidi B Staels, Arterioscler Thromb Vasc Biol 2008 28 1050 1059 10.1161/ATVBAHA.107.158998 18323516
41. Pregnane X receptor prevents hepatorenal toxicity from cholesterol metabolites. J Sonoda LW Chong M Downes GD Barish C Liddle CH Lee RM Evans, PNAS 2005 102 2198 2203 10.1073/pnas.0409481102 15671183
42. PXR induces CYP27A1 and regulates metabolism in the intestine. T Li W Chen JYL Chiang, J Lipid Res 2007 48 373 384 10.1194/jlr.M600282-JLR200 17088262
43. Influence of the HDL receptor SR-BI on lipoprotein metabolism and atherosclerosis. BL Trigatti M Krieger A Rigotti, Arterioscler Thromb Vasc Biol 2003 23 1723 1738 10.1161/01.ATV.0000091363.28501.84 (Pubitemid 37254855)
44. ATP-binding cassette transporter AI: A cell cholesterol exporter that protects against cardiovascular disease. JF Oram AM Vaughan, Physiol Rev 2005 85 1343 1372 10.1152/physrev.00005.2005 16183915
45. Regulation of plasma high-density lipoprotein levels by the ABCA1 transporter and the emerging role of high-density lipoprotein in the treatment of cardiovascular disease. HB Brewer Jr AT Remaley EB Neufeld F Basso C Jouce, Arterioscler Thromb Vasc Biol 2004 24 1755 1760 10.1161/01.ATV.0000142804.27420. 5b 15319263
46. Transcriptional regulatory networks in lipid metabolism control ABCA1 expression. G Schmitz T Langmannn, Biochim Biophys Acta 2005 1735 1 19 15922656
47. HDL biogenesis and cellular cholesterol homeostasis. S Yokoyama, Ann Med 2008 40 29 38 10.1080/07853890701727429 (Pubitemid 351199338)
48. Nonagenarian siblings and their offsprings display lower risk of mortality and morbidity than sporadic nonagenarians: The Leiden longevity study. RGJ Westendorp D van Heemst MP Rozing MF Frölich SP Moijaart GJ Blauw M Beekman BT Heijmans AMJ de Craen PE Slagboom Leiden Longevity Study Group, JAGS 2009 57 1634 1637 10.1111/j.1532-5415.2009.02381.x
49. Aging and HDL metabolism in elderly people more than 100 years old. Y Arai N Hirose, J Atheroscler Thromb 2004 11 246 252 15557706
50. Lipid profile variations in a group of healthy elderly and centenarians. M Malaguernara I Giugno P Ruello M Rizzo MP Panebianco G Pistone FB Tomasello, Eur Rev Med Pharmacol Sci 1998 2 75 79 10229562
51. Implications from and for food cultures for cardiovascular disease: longevity. M Suzuki BJ Wilcox CD Wilcox, Asia Pac J Clin Nutr 2001 10 165 171 10.1046/j.1440-6047.2001.00219.x 11710359
52. Unique lipoprotein phenotype and genotype associated with exceptional longevity. N Barzilai G Atzmon C Schechter EJ Schaefer AL Cupples R Lipton S Chen AR Shuldiner, JAMA 2003 290 2030 2040 10.1001/jama.290.15.2030 14559957
53. Cardiovascular advantages among the offspring of centenarians. DT Terry M Wilcox MA McCormick E Lawler TT Perls, J Gerontol: Med Sci 2003 58A 428 431
54. Offsprings of centenarians have a favorable lipid profile. N Barzilai I Gabriely M Gabriely N Iankowitz JD Sorkin, JAGS 2001 49 76 79 10.1046/j.1532-5415.2001.49013.x (Pubitemid 32197302)
55. Increasing apoA-I production as a target for CHD risk reduction. SPJ Dullens J Plat RP Mensink, Nutrition Metab & Cardiovasc Dis 2007 17 618 628
56. Extended- release niacin alters the metabolism of plasma apoliprotein (apo) A-I and apo-B containing lipoproteins. S Lamon-Fava MR Diffenderfer PHR Barrett A Buchsbaum M Nyaku KV Horvath BF Asztalos S Otokozawa M Ai NR Matthan AH Lichtenstein GG Dolonikowski EJ Schaefer, Arteriosclerosis Thromb Vasc Biol 2008 28 1672 1678 10.1161/ATVBAHA.108.164541
57. The effect of select nutrients on serum high-density lipoprotein cholesterol and apolipoprotein A-I levels. AD Mooradian MJ Haas NCW Wong, Endocrine Reviews 2006 27 2 16 10.1210/er.2005-0013 16243964
58. Cytochrome P450 and gene activation - from pharmacology to cholesterol elimination and regression of atherosclerosis. PV Luoma, Eur J Clin Pharmacol 2008 64 841 850 10.1007/s00228-008-0515-5 18633604
59. Diet-dependent cardiovascular lipid metabolism controlled by hepatic LXR M Lehrke C Lebherz SC Millington HP Guan J Milllar DJ Rader JM Wilson MA Lazar, Cell Metab 2005 1 297 308 10.1016/j.cmet.2005.04.005 16054077
60. Beyond established and novel risk factors: lifestyle risk factors for cardiovascular disease. D Mozaffarian PWF Wilson WB Kannel, Circulation 2008 117 3031 3038 10.1161/CIRCULATIONAHA.107.738732 18541753
61. Diet and exercise in the management of hyperlipidemia. RB Kelly, Am Fam Physician 2010 81 1097 1102 20433126
62. Adherence to a Mediterranien diet and survival in a Greek population. A Trichopoulou T Costacou C Bamia D Trichopoulos, New Engl J Med 2003 348 2599 2608 10.1056/NEJMoa025039 12826634
63. Effects of a Mediterranien-style diet on cardiovascular risk factors. A randomized trial. R Estruh MA Martinez-Gonzalez D Corella J Salas-Salvado V Ruiz-Gutierrez MI Covas M Fiol E Gomez-Gracia MC Lopez-SAbater E Vinyoles F Aros M Conde C Lahoz J Lapetera G Saez E Ros PREDIMED Study investigators, Ann Intern Med 2006 145 1 11 16818923
64. Mediterranien dietary pattern and prediction of all-cause mortality in a US population. PN Mitrou V Kipnis ACM Thièbaut J Reedy AF Subar E Wirfält A Flood T Mouw AR Hollenbeck MF Leitzmann A Schatzkin, Arch Int Med 2007 167 2481 2488 10.1001/archinte.167.22.2461 (Pubitemid 350254905)
65. The effect of physical exercise on reverse cholesterol transport. DA Leaf, Metabolism 2004 52 950 957 10.1016/S0026-0495(03)00147-1
66. Low-intensity exercise exerts beneficial effects on plasma lipids via PPAR LR Butcher A Thomas K Backx A Roberts R Webb K Morris, Medicine & Science in Sports & Exercise 2008 40 1263 70 10.1249/MSS.0b013e31816c091d
67. Physical fitness and reverse cholesterol transport. B Olchawa BA Kingwell A Hoang L Schneider O Miyazaki P Nestel D Sviridoov, Arterioscler Thromb Vasc Biol 2004 24 1087 91 10.1161/01.ATV.0000128124.72935.0f 15072992
68. Enhanced cholesterol efflux promotion in well-trained soccer players. F Brites J Verona C De Geitere JC Fruchart G Castro R Wikinski, Metabolism 2004 53 1262 1267 10.1016/j.metabol.2004.05.002 15375780
69. Physical activity and lipoprotein disorders. A Berg I Frey MW Baumstark M Halle J Keul, Sports Med 1994 17 6 21 10.2165/00007256-199417010-00002 8153500
70. Endurance exercise training reduces gallstone development in mice. KR Wilund LA Feeney EJ Tomayko HR Chung K Kim, J Appl Physiol 2008 104 761 765 10.1152/japplphysiol.01292.2007 18187606
71. Influence of exercise, walking, cycling, and overall nonexercise physical activity in mortality in Chinese women. CE Matthews AL Jurj X Shu HL Li G Yang Q Li YT Gao W Zheng, Amer J Epidemiol 2007 165 1343 1350 10.1093/aje/kwm088 (Pubitemid 47234317)
72. Physical activity protects against coronary death and death from all causes in middle-aged men. Evidence from a 20-year follow-up of the primary prevention study in Göteborg. A Rosengren L Wilhelmsen, Ann Epidemiol 1997 7 69 75 10.1016/S1047-2797(96)00106-8 9034409
73. Genes encoding longevity: from model organisms to humans. M Kuningas SP Mooijart D van Heemst BJ Zwaan PE Slagboom GJ Westendorp, Aging Cell 2008 7 270 280 10.1111/j.1474-9726.2008.00366.x 18208581
74. Gene-activators prevent and regress atherosclerosis and reduce mortality. PV Luoma, Cardiovasc Hematol Agents Med Chem 2009 7 295 304 10.2174/187152509789541918 19607643
75. Comparison of the effects of high doses of rosuvastatin versurs atorvastatin on the subpopulations of high-density lipoproteins. BF Asztalos F Le Maulf GE Dallal E Stein PH Jones KV Horvath F McTaggart EJ Schaefer, Am J Cardiol 2007 99 681 685 10.1016/j.amjcard.2006.09.117 17317371
76. Regulation of human cytochrome P450 4F2 expression by sterol regulatory element-binding protein and lovastatin. MH Hsu Savas KJ Griffin EF Johnson, J Biol Chem 2007 282 5225 5236 10.1074/jbc.M608176200 17142457
77. Sterol regulatory element-binding protein-2 and liver X receptor-driven dual promoter regulation of hepatic ABC transporter A1 gene expression. Mechanism underlying the unique response to cellular cholesterol status. N Tamehiro Y Shigemoto-Mogami T Kakeya K Okuhira K Suzuki S Sato R T Nagao T Nishimaki-Mogami, J Biol Chem 2007 282 21090 9 10.1074/jbc.M701228200 17526932
78. Stimulation of CD36 and the key effector of reverse cholesterol transport ATB-binding cassette A1 in monocytoid cells. T Rubic M Trottmann RL Lorenz, Biochem Pharmacol 2004 67 411 419 10.1016/j.bcp.2003.09.014 15037193
79. Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism. J Shepherd CJ Packard JR Patsh AM Gotto Jr OD Taunton, J Clin Invest 1979 63 858 867 10.1172/JCI109385 221531
80. Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus statin alone (the COMPELL study). JM McKenney PH Jones HE Bays RH Knopp ML Kashyap GE Ruoff ME MCGovern, Atherosclerosis 2007 192 432 437 10.1016/j.atherosclerosis.2006.11.037 17239888
81. High density apolipoprotein metabolism. J Shepherd CJ Packard, Clinical and Metabolic Aspects of High- density Lipopropteins Amsterdam: Elsevier, Miller NE, Miller GJ, 1984 247 274
82. Regulation of hepatic low-density lipoprotein receptor, 3-hydroxy-3-methylglutaryl coenzyme A reductase, and cholesterol 7-hydroxylase mRNAs in human liver. M Rudling B Angelin L Ståhle E Reihnèr S Sahlin H Olivecrona I Björkhem C Einarsson, J Clin Endocrinol Metab 2002 87 4307 4313 10.1210/jc.2002-012041 12213890
83. Early effect of lipid-lowering therapy with pitavastain on regression of coronary atherosclerotic plaque - comparison with atorvastatin. T Toi I Taguchi S Yoneda M Kageyama A Kikuchi M Tokura T Kanaya S Abe R Matsuda N Kaneko, Circ J 2009 73 1466 1472 10.1253/circj.CJ-08-1051 19531899
84. Effect of fluvastatin on progression of coronary atherosclerotic plaque evaluated by virtual histology ultrasound. J Nasu E Tsuchikane O Katoh N Tanaka M Kimura M Ehara Y Kinoshita T Matsubara H Matsuo K Asakura Y Asakura T Terashima T Takayama J Honey A Hirayama S Saito T Suzuki, JACC Cardiovasc Interv 2009 2 689 696 10.1016/j.jcin.2009.04.016 19628194
85. Association of leucocyte subtype counts with coronary atherosclerotic regression following pravastatin treatment. S Tani K Nagao T Anazawa H Kawamata S Furuya H Takahashi K Tida M Matsumoto T Washio N Kumabe A Hirayama, Am J Cardiol 2009 104 464 469 10.1016/j.amjcard.2009.04.009 19660595
86. Statins, high- density lipoprotein cholesterol and regression of coronary atherosclerosis. SJ Nicholls E Murat I Sipahi AW Grasso P Schoenhagen T Hu K Wolski T Crowe MY Desai SL Hazen SR Kapadia SE Nissen, JAMA 2007 297 499 508 10.1001/jama.297.5.499 17284700
87. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomized controlled trials. JJ Brugts T Yetgin SE Hoeks AM Gotto J Shepherd RGJ Westendorp AJM de Craen RH Knopp H Nakamura P Ridker R van Domburg JW Deckers, BMJ 2009 338 2376 10.1136/bmj.b2376 19567909
88. Decrease in mortality rate of chronic obstructive pulmonary disease (COPD) with statin use: A population-based analysis in Japan. W Ishida T Kajiwara M Ishii F Fujiwara H Taneichi N Takebe K Takahahi Y Kaneko I Segawa H Inoue J Satoh, Tohoku J Exp Med 2007 212 265 273 10.1620/tjem.212.265 17592214
89. Comparison of mortality rates in statin users versus nonstatin users in a United States veteran population. JL Mehta Z Bursac M Hauer-Jensen C Fort LM Fink, Am J Cardiol 2006 98 923 928 10.1016/j.amjcard.2006.04.033 16996875
90. Extended-release niacin or ezetimibe and carotid intima-media thickness. AJ Taylor TC Villines EJ Stanek PJ Devine L Griffen M Miller NJ Weissman M Turco, N Engl J Med 2009 361 2113 2122 10.1056/NEJMoa0907569 19915217
91. Ten - year all-cause mortality in presumably healthy subjects on lipid-lowering drugs (from the Prospective Epidemiological Study of Myocardial Infarction [Prime] prospective cohort). V Gardette V Bongard J Dallongeville D Arveiler A Bingham J.B Ruidavets P Amouyel B Haas P Ducimetièr J Ferrières, Am J Cardiol 2009 103 381 386 10.1016/j.amjcard.2008.09.092 19166693
92. Gemfibrozil in the treatment of dyslipidemia. An 18-year mortality follow-up of the Helsinki Heart Study. L Tenkanen M Mänttäri PT Kovanen H Virkkunen V Manninen, Arch Intern Med 2006 166 743 748 10.1001/archinte.166.7.743 16606810
93. Effects on coronary artery disease of lipid lowering diet, or diet plus cholestyramine. In St Thomas Atherosclerosis Regression Study (STARS). GF Watts B Lewis JNH Brunt ES Lewis DJ Coltart LD Smith JI Mann AV Swan, Lancet 1992 339 563 539 10.1016/0140-6736(92)90863-X 1347091
94. A one-year study of the antiatherosclerotic effect of the angiotensin-II receptor blocker Losartan in hypertensive patients. M Sonoda T Aoyagi K Takenak K Uno R Nagai, Int Heart J 2008 49 95 103 10.1536/ihj.49.95 18360068
95. Impact of angiotensin II receptor blockers on the progression and regression of coronary atherosclerosis. An intravascular ultrasound study. K Waseda Y Ozaki H Takashima A Junya T Yasukawa TF Ismail H Hishida I Takayuki, Cir J 2006 70 1111 1115 10.1253/circj.70.1111 (Pubitemid 44386988)
96. Effect of amlopidine on vascular responses after coronary stenting compared with an angiotensin-converting enzyme inhibitor. T Yamazaki I Taniguchi T Kurusu Y Shimazu Y Hashizume K Takikawa M Kuwata T Onodera M Yoshikawa S Mochizuki, Circ J 2004 68 328 333 10.1253/circj.68.328 15056829
97. Systematic review: comparative effectiness of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for ischemic heart disease. WL Baker CI Coleman J Kluger KM Reinhart R Talati R Qercia OJ Phung CM White, Ann Int Med 2009 151 861 871 20008762
98. Calcium channel blockers and cardiovascular outcomes: a meta-analysis of 175634 patients. P Costanzo P Perrone-Filardi M Petretta C Marciano E Vassallo P Gargiulo S Paolillo A Petretta M Chiariello, J Hypertens 2009 27 1136 1151 10.1097/HJH.0b013e3283281254 19451836
99. High-density lipoproteins, inflammation and oxidative stress. F Tabet KA Rye, Clin Science 2009 116 87 98 10.1042/CS20080106
100. Effects of nifedipine GITS and atenolol monotherapy on serum lipids, blood pressure, heart rate, and weight in mild to moderate hypertension. MC Houston L Olafsson MC Burger, Angiology 1991 42 681 690 10.1177/ 000331979104200901 1928808
101. Favorable effect of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes. JM Lawrence C Stirling J Reid JPD Reckless GJ Taylor, Diabetes Care 2004 27 41 46 10.2337/diacare.27.1.41 14693964 (Pubitemid 38196707)
102. A prospective trial of phenytoin in nonepileptic subjects with reduced HDL cholesterol. M Miller RG Burgan L Osterlund JP Segrest DW Garber, Arterioscler Thromb Vasc Biol 1995 15 2151 2156 7489236
103. 2in alcohol consumers. C Schaefer A Parlesak J Eckoldt C Bode JC Bode W März K Winkler, J Lipd Res 2007 48 1550 8 10.1194/jlr.M600513-JLR200 (Pubitemid 47312016)
104. Relation of angioraphically defined coronary artery disease to plasma lipoprotein subfractions and apolipoproteins. NE Miller F Hammett S Saltissi S Rao H van Zeller J Coltart B Lewis, Brit Med J 1981 282 1741 1744 10.1136/bmj.282.6278.1741
105. Cytochrome P450 - physiological key factor key factor against cholesterol accumulation and the atherosclerotic vascular process. PV Luoma, Ann Med 2007 39 359 370 10.1080/07853890701379767 17701478
106. Relationship between lipid composition and drug metabolizing capacity of human liver. MJ Savolainen AJ Arranto IE Hassinen PV Luoma RO Pelkonen EA Sotaniemi, Eur J Clin Pharmacol 1985 27 727 732 10.1007/BF00547057 3987778
107. ABCA1 and ABCG1 synergize to mediate cholesterol export to apoA-I. IC Gelissen M Harris KA Rye C Quinn AJ Brown M Kockx S Cartland M Pachianatham L Kritharides W Jessup, Arterioscler Thromb Vasc Biol 2006 26 534 540 10.1161/01.ATV.0000200082.58536.e1 16357317
108. 2bparticles. SM Mäkelä M Jauhiainen M Ala-Korpela J Metso TM Lehto MJ Savolainen ML Hannuksela, Alcoholism: Clin Exper Res 2008 32 991 1000 10.1111/j.1530-0277. 2008.00660.x (Pubitemid 351733082)
109. Serum levels of high-density lipoprotein phospholipids correlate with severity of angiographically defined coronary disease. SL Hsia R Duncan AH Schob SC Chakko R Mulingtabang JL He GO Perez, Atherosclerosis 2000 152 469 473 10.1016/S0021-9150(99)00499-2 10998476
110. Hydroxycholesterol regulators of 3-hydroxy-3-methylglutaryl-CoA reductase in liver. Effect of dietary cholesterol. SE Saucier AA Kandutsch AK Gayen DK Swahn TA Spencer, J Biol Chem 1989 264 6863 6869 2708346
111. ABCA1mRNA and protein distribution patterns predict multiple different roles and levels of regulation. CL Wellington EKY Walker A Suarez A Kwok N Bissada R Singaraja YZ Yang LH Zhang E James JE Wilson O Francone BM Mcmanus MR Hayden, Lab Invest 2002 82 273 283 11896206
112. Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney catabolism of apoA-I. JM Timmins JY Lee E Boydyguina KD Kluckman LR Brunham A Mulya AK Gebre JM Coutinho PL Colvin TL Smith MR Hayden N Meda JS Parks, J Clin Invest 2005 115 1333 1342 15841208
113. Tissue-specific roles of ABCA1 influence susceptibility to atherosclerosis. LR Brunham RR Singaraja M Duong JM Timmins C Fievet N Bissada MH Kang A Samra JC Fruchart B Mcmanus B Staels JS Parks MR Hayden, Arterioscler Thromb Vasc Biol 2009 29 548 554 10.1161/ATVBAHA.108.182303 19201688
114. HDL: a recipe for longevity. P Barter, Atherosclerosis Supplements 2004 5 25 31 10.1016/j.atherosclerosissup.2004.03.003 15121032
115. Plasma HDL levels correlate with cognitive function in exceptional longevity. G Atzmon I Gabriely W Greiner D Davidson C Schechter N Barzilai, J Gerontol: Med Sci 2002 57A 712 M715